Category:

Research

The data suggests that, despite common inflammatory mechanisms, people with cystic fibrosis may present a form of COVID-19 that is often less severe than expected, possibly thanks to cellular characteristics of CF and the potential protective effect of CFTR modulators.

The Fall 2024 issue of Santé Vous Bien highlights the inspiring journeys of people living with cystic fibrosis, from climbing Mount Kilimanjaro to lung transplantation, sports, literature, and research to show that CF does not set limits to the heights that can be reached.

A file that traces the major advances in lung transplantation for people with cystic fibrosis, highlighting their resilience, the evolution of transplant criteria and the major impact of treatments such as Trikafta.

Quebec study drawing up a current socio-demographic portrait of people living with cystic fibrosis in order to better adapt services and defend their rights.

This 2022 update presents the major advances in cystic fibrosis research, marked by the arrival of CFTR modulators (ETI/Trikafta), their major benefits, emerging clinical challenges and research paths for ineligible people.

A historical look at the evolution of cystic fibrosis through the researchers, clinicians, and committed individuals who have shaped its understanding and management.

In people with cystic fibrosis, some resistance to antibiotics caused by Pseudomonas aeruginosa may paradoxically increase bacterial virulence, complicating lung infections and opening the way to new therapeutic approaches.

The addition of Trikafta to the RAMQ in September 2021 marks a major advance for cystic fibrosis in Quebec by making available a treatment that acts on the cause of the disease for eligible people.

Research has profoundly improved the prognosis of cystic fibrosis thanks to CFTR modulators, with new hope for all patients despite challenges in accessing treatments.

The article presents major advances in research targeting the CFTR protein, with innovative therapies (ivacaftor, lumacaftor and combinations) that pave the way for a gradual correction of the very cause of cystic fibrosis.

Vascular access is essential for intravenous treatment for cystic fibrosis, but each type of catheter has benefits and risks that should be well understood in order to prevent complications.

New emerging pathogens in cystic fibrosis (MRSA, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans) are becoming more and more frequent, but their exact impact on lung function and survival is still partially unclear.

An overview of major research advances in 2014, marking the transition to treatments that directly target the genetic defect in cystic fibrosis.

An overview of the history of cystic fibrosis, from early ancient observations to modern medical advances.

A look back at the major advances in cystic fibrosis research presented at the 2016 North American Conference, in particular the identification of the CFTR gene and the development of treatments that target the fundamental defect of the disease.

A study explains how adults living with cystic fibrosis seek a balance between quality of life, psychosocial adjustment and adherence to demanding treatment, influenced in particular by the perception of the disease, the feeling of coherence and the relationship with the health care team.

The year 2017 marked a major turning point in cystic fibrosis, with promising advances towards combination therapies capable of correcting the genetic defect in the majority of people affected.

Inventor of the Frequencer and a leading figure in the FK community, Louis Plante leaves a lasting legacy of innovation, courage and hope.

Scientific advances in cystic fibrosis are major, but access to treatments remains unequal. A call for equity and mobilization.

A Canadian study that reveals the importance of mental health needs and the lack of access to psychological services among adults with cystic fibrosis.